Evotec SE (NASDAQ:EVO - Free Report) - Investment analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for shares of Evotec in a research report issued on Monday, April 21st. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($0.05) per share for the quarter, down from their prior forecast of ($0.01). The consensus estimate for Evotec's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec's Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.20) EPS and FY2026 earnings at $0.00 EPS.
Evotec Price Performance
NASDAQ:EVO opened at $3.97 on Wednesday. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average of $3.66 and a 200 day moving average of $4.07. Evotec has a 52 week low of $2.84 and a 52 week high of $7.77.
Hedge Funds Weigh In On Evotec
Several hedge funds and other institutional investors have recently modified their holdings of EVO. BNP Paribas Financial Markets purchased a new position in Evotec during the 4th quarter valued at about $27,000. CSS LLC IL bought a new position in shares of Evotec during the fourth quarter valued at approximately $50,000. Bank of America Corp DE lifted its stake in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares during the period. Lighthouse Investment Partners LLC bought a new stake in Evotec in the fourth quarter valued at $166,000. Finally, DCF Advisers LLC increased its position in Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after purchasing an additional 12,816 shares during the period. 5.81% of the stock is owned by institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
